WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Post Traumatic Stress Disorder Management: Pharmacological and Psychological Therapies

Drisya T [1*], A. R Shabaraya [2], Lathika A Nayak [3]

[1] Pharm D Intern, Srinivas College of Pharmacy, Valachil, Mangaluru, Karnataka State, India, E-mail: drisyat1381@gmail.com

[2] Principal and Director, Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil Post, Farangipete, Mangaluru, Karnataka State, India; E-mail: scpprincipal@srinivasgroup.com

[3] Assistant Professor, Department of Pharmacy practice, Srinivas College of Pharmacy, Valachil post, Farangipete, Mangaluru, Karnataka State, India; E-mail: nayaklathika57@gmail.com

*Corresponding Author:

Drisya T, Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil post, Farangipete, Mangaluru – 574143, Karnataka, India; Email: drisyat1381@gmail.com

DOI : https://doi.org/10.55248/gengpi.5.1224.0238

ABSTRACT:

Post-traumatic stress disorder (PTSD) is a psychiatric disorder characterized by the development of intrusive symptoms, avoidance of trauma cues, negative changes in cognition, and mood. Symptoms of intrusion, avoidance/numbing, hyperarousal, stress or sensitivity, irritability, hypervigilance, sleep disturbances, lack of concentration, or emotions related to a traumatic event through sensory flashbacks or nightmares are all symptoms of PTSD. The possible psycho-pathological consequence of exposure to a traumatic event that threatens a person's psychological and/or physical integrity. DSM-5 states that symptoms must be present for one month after the traumatic event to be diagnosed with PTSD. Psychotherapy and medication are both effective treatments for PTSD. During the first 4 weeks after a traumatic event, psychotherapy or pharmacotherapy, including benzodiazepines, is not necessary. Current treatment guidelines recommend 3 first-line trauma-focused treatments: prolonged exposure (PE), cognitive transformation therapy (CTT), and eye movement desensitization and reprocessing (EMDR). The pharmacological therapy include SSRIs and Venlafaxine are first line pharmacotherapy for PTSD. Sertraline and Paroxetine have received approval for the immediate treatment of PTSD, while Sertraline is also approved for long-term care. Mirtazapine was effective in doses upto 45mg/day and is a second line agent. Amitriptyline and Imipramine are considered second-line options. Phenelzine is a third line drug.

Keywords: *Post Traumatic Stress Disorder(PTSD), neurotransmitter, psychotherapy, anti-psychotic.*

Introduction

Post-traumatic stress disorder (PTSD) is a psychiatric disorder characterized by the development of intrusive symptoms, avoidance of trauma cues, negative changes in cognition, and mood[1]. Symptoms of intrusion, avoidance/numbing, hyperarousal, stressors sensitivity, irritability, hyper-vigilance, sleep disturbances, lack of concentration, or emotions related to a traumatic event through sensory flashbacks or nightmares are all symptoms of PTSD[2,3]. This is a possible psycho-pathological consequence of exposure to a traumatic event that threatens a person's psychological and/or physical integrity[3,4]. The negative effects of PTSD can often be long-lasting because it causes a reduction in overall functioning, and many people with PTSD are reluctant to seek treatment[5]. The prevalence of PTSD varies among populations, with higher rates observed in people with a history of exposure to severe trauma, such as veterans, survivors of sexual assault, and refugees. According to the National Center for PTSD, approximately 7 to 8 percent of the U.S. population will experience PTSD at some point in their lives, with significant consequences for public health and social well-being. In high-risk populations, the prevalence of PTSD is estimated to be 15.4%[6]. PTSD is associated with significant physical and psychiatric comorbidities, including substance abuse and suicide[7]. Traumatic stress is associated with exposure to actual or threatened injury, death, or sexual assault[8].

Exposure to traumatic stress is a trigger for the development of PTSD. For this reason, a distinction between ordinary and traumatic stressors (those that have the potential to lead to PTSD) is necessary. PTSD was initially identified in the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), with subsequent updates to the diagnostic criteria being introduced in later versions. DSM-5 states that symptoms must be present for one month after the traumatic event to be diagnosed with PTSD[9]. Acute stress disorder (ASD) presents with symptoms similar to PTSD, is diagnosed 3 days to 1 month after trauma, and is a strong predictor of PTSD[10]. There is a need for therapies designed to prevent the advancement of early traumatic stress reactions into chronic PTSD, especially in individuals at high-risk, to reduce this significant morbidity.

While some psychological interventions aimed at preventing the development of PTSD are ineffective[11] and others, such as post-traumatic psychological debriefing, may even be harmful, there is evidence of the benefits of trauma-focused cognitive behavioral therapy in the treatment of individuals with acute symptoms. Traumatic stress and preliminary work on prolonged exposure therapy immediately following trauma have shown promise in reducing post-traumatic stress reactions[12]. The limited evidence available for treatments that integrate psychological and pharmacological intervention, however, has so far not shown significant benefit[13].

MANAGEMENT OF PTSD

Psychotherapy and pharmacotherapy are effective option for treating PTSD. However, a significant number of people who seek treatment experience symptoms that are difficult to treat[2].

Initial Management

The majority of individuals who experience trauma do not go on to develop acute stress disorder or PTSD. During the first 4 weeks after a traumatic event, psychotherapy or pharmacotherapy, including benzodiazepines, is not necessary. Psychological debriefing, a brief intervention provided in a group setting during the first 2 weeks after a traumatic event, may interfere with natural recovery and is generally not recommended. During this initial phase, the goal is to help patients understand that acute responses to trauma are common and often short-lived. They allow them to use their natural resilience and usual emotional support to recover. There is little evidence that taking medication immediately after a traumatic event can prevent the onset of PTSD. For people who feel overwhelmed and whose functioning is weakened, it may be necessary to start supportive psychotherapy or drug treatment in the first four weeks after the traumatic event. Treatment for PTSD can vary depending on the severity and chronicity of trauma symptoms and the presence of co-morbid disorders. Most often, a phased treatment approach is used, which includes behavioral stabilization, psycho-education, anxiety management, trauma-focused psychotherapy, relapse prevention, and follow-up care. Treat mood disorders as the primary condition if they are severe enough to interfere with PTSD treatment. It is important to manage the associated chronic pain and sleep disturbances in patients with PTSD. PTSD patients often attempt to self-medicate and may suffer from substance use disorders.

NON-PHARMACOLOGICAL MANAGEMENT

Trauma-focused psychotherapy is recommended as first-line treatment before starting pharmacotherapy. However, pharmacotherapy is also recommended as first-line treatment when trauma-focused psychotherapy is not available or preferred, or if stabilization is required[14]; Pharmacotherapy may also be more effective than psychotherapy for military or war-related PTSD. The PTSD guidelines could not make a clear recommendation regarding the combination of psychotherapy and pharmacotherapy, but a study published after the guidelines did not show a significant difference between other single or combined approaches. PTSD patients should be offered the choice that best suits their situation and available resources. Various psychological approaches have been studied in the treatment of PTSD and acute stress disorder. The main goal of psychotherapy is to reduce the severity of symptoms and improve quality of life and functioning in social and occupational settings.

PSYCHOTHERAPIES FOR POST-TRAUMATIC STRESS DISORDER

Current treatment guidelines recommend 3 first-line trauma-focused treatments: prolonged exposure (PE), cognitive transformation therapy (CTT), and eye movement desensitization and reprocessing (EMDR).

PROLONGED EXPOSURE (PE)

Prolonged exposure (PE) therapy was created by Edna Foa and consists of 8 to 15 sessions, each lasting 90-minutes. PE targets avoidance as a symptom that impedes recovery by helping the client engage in activities that they avoid due to the trauma and repeated exposure to traumatic memories. PE is one of the most widely studied treatments for PTSD, with over 20 randomized controlled trials (RCTs). Results of meta-analyses of RCTs and comparisons with wait-list control conditions have shown that it results in significant reductions in the size of the treatment effect on PTSD symptoms and loss of diagnosis[15].

COGNITIVE PROCESS THERAPY (CPT)

CPT was developed by Patricia Resick. This is a 12-session, 60-minute manualized treatment. It focuses on addressing the cognitive symptoms associated with PTSD that maintain avoidance of negative affect. Like PE, CPT is a well-studied treatment, with over 20 RCTs across traumas, populations, and countries. Meta-analyses evaluating RCTs compared to wait-list control conditions and treatment as usual (TAU) have found that CPT produced large reductions in effect sizes on PTSD symptoms and attrition.[15],[16].

EYE MOVEMENT DESENSITIZATION AND REPROCESSING (EMDR)

EMDR was developed by Francine Shapiro. It is usually administered in weekly sessions of up to 90 minutes over a period of 3 months, although the length of treatment varies according to the needs of the individual. It focuses on reducing the intensity of traumatic memories through eye movements; however, this mechanism is the subject of ongoing scientific debate[17]. EMDR is the subject of growing research, with over 40 trials evaluated in a meta-analysis[17]. EMDR has been shown to have a strong effect in the treatment of PTSD[18].

In general, when it comes to treating PTSD, there is evidence that the most supported treatments are PE and CBT. However, meta-analyses have also found that there is no strong evidence for the clear superiority of any particular intervention, indicating that what is important is that affected people receive treatment[19].

CONSIDERATIONS FOR PHARMACOLOGICAL PREVENTION EFFORTS FOR POST-TRAUMATIC STRESS DISORDER

In the first hours and days after a traumatic experience, many people report symptoms of acute stress, including increased arousal, insomnia, and agitation[20]. Although benzodiazepines (BZDs) are effective in reducing these symptoms, they are ineffective in preventing PTSD[21]. Patients newly prescribed BZDs should be informed of the risk of addiction and closely monitored. Evidence for the efficacy of other pharmacological agents, including beta-blockers, opiates, and hydrocortisone, in preventing PTSD after traumatic experience is sparse and of low quality.

As monotherapy, there is the most reliable and extensive evidence for the efficacy of sertraline, paroxetine, fluoxetine (3 selective serotonin reuptake inhibitors [SSRIs]) and venlafaxine extended-release (serotonin norepinephrine reuptake inhibitor [SNRI])[22]. Based on the mechanism of action of these drugs, it can be assumed that the entire class of SSRIs is effective. SSRIs and SNRIs have essentially replaced the older antidepressants that are effective against PTSD, tricyclic antidepressants and monoamine oxidase inhibitors, due to their superior safety and tolerability profiles. However, a tricyclic has shown similar efficacy to an SSRI in a head-to-head comparison, suggesting that the older drugs may not be useful in patients resistant to newer drugs. In addition, the efficacy of quetiapine, an atypical antipsychotic, has also been documented[23]. However, due to its adverse effect profile and lack of tolerability.

PHARMACOLOGICAL MANAGEMENT OF PTSD

Pharmcological management of PTSD depends on the nature, severity, and frequency of the trauma and requires a multimodal treatment program. Short-term medication treatment may be beneficial for patient who do not have access to trauma focused therapy. Pharmacological management of PTSD typically involves the use of specific medications that target neurotransmitter systems associate with anxiety and mood regulation. Several intervention options, such as psychotherapy, benzodiazepines and antispychotics are available for PTSD[24].

FIRST LINE THERAPY FOR PTSD

Selective Serotonin Reuptake Inhibitors (SSRIs) :

Fluoxetine

Fluoxetine, a selective serotonin re-uptake inhibitor (SSRI), has been recognized as an effective treatment for PTSD, particularly in reducing core symptoms associated with the disorder[25]. Its use is supported by numerous clinical trials that have shown significant improvements compared to placebo. However, response rates can vary between individuals, indicating the need for personalized treatment approaches[26].

Fluoxetine is a selective neuronal serotonin reuptake inhibitor, which can increase synaptic levels of serotonin to facilitate serotonergic neurotransmission. It works by increasing levels of serotonin in the brain, which is thought to play a crucial role in the regulation of mood and anxiety disorders. This mechanism is essential for alleviating core symptoms of PTSD, such as intrusive thoughts and hyperarousal[27].

Although fluoxetine is effective, its response rate is not universally high; studies suggest that less than 30% of patients achieve complete remission even with SSRIs. Other SSRIs, such as sertraline and paroxetine, are also recommended for PTSD, but fluoxetine remains a commonly used option due to its favorable side effect profile and efficacy[26].

Sertraline

Sertraline is a selective serotonin reuptake inhibitor (SSRI) known to be an effective treatment for post-traumatic stress disorder (PTSD). Research shows that sertraline has significant efficacy in reducing PTSD symptoms, particularly in the areas of avoidance/numbing and hyperarousal. One study found that improvements were evident by the second week of treatment, with significant reductions in Physician-Administered PTSD Scale (CAPS-2) scores compared to placebo groups[28].

In a randomized clinical trial, patients treated with sertraline demonstrated sustained improvement in PTSD symptoms over a 24-month follow-up period, highlighting its potential for long-term management. Although sertraline is effective, studies suggest that trauma-focused therapies may produce faster results in some areas of social functioning compared with medication alone. However, sertraline remains an essential option for people who are unable or unwilling to engage in psychotherapy[29].

Paroxetine

Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is known to be effective in the treatment of posttraumatic stress disorder (PTSD). It is one of the few drugs approved by the U.S Food and Drug Administration (FDA) specifically for this condition, along with sertraline[30]. Research shows that paroxetine is effective in reducing PTSD symptoms across all major symptom clusters: reexperiencing, avoidance/numbing, and hyperactivity. A major study randomized patients with chronic PTSD to receive placebo, 20 mg, or 40 mg of paroxetine daily for 12 weeks. Results showed significant improvements in patients receiving paroxetine compared with the placebo group, with both doses being well tolerated. Paroxetine works by increasing levels of serotonin in the brain, which is thought to play a crucial role in regulating mood and anxiety disorders. This mechanism is particularly relevant given the neurobiological abnormalities observed in PTSD patients, such as alterations in the hypothalamic-pituitary-adrenal (HPA) axis and neurotransmitter systems[31].

Paroxetine stands out as an effective treatment option for adults with chronic PTSD. Its approval by regulatory agencies highlights its established role in the pharmacotherapy of this disease. Although generally well tolerated, individual responses may vary, requiring personalized treatment approaches based on patient history and symptom profiles[32].

Serotonin Nor-epinephrine Reuptake Inhibitors (SNRI)

Venlafaxine

Venlafaxine, a serotonin norepinephrine reuptake inhibitor (SNRI), has been studied for its effectiveness in the treatment of post-traumatic stress disorder (PTSD). It is particularly known for its ability to treat symptoms related to the dysregulation of serotonin and norepinephrine, which are believed to play a role in PTSD.

Research shows that extended-release venlafaxine (Effexor XR) is effective in reducing symptoms of PTSD. A large study of 329 adults diagnosed with PTSD showed that those treated with venlafaxine had a significant reduction in symptoms compared to a placebo group.

Venlafaxine works by inhibiting the reuptake of serotonin and norepinephrine, which may help alleviate symptoms associated with hyperarousal and the reoccurrence of core PTSD features. This dual action is considered beneficial given the role of noradrenergic pathways in PTSD. Discontinuation of venlafaxine should be considered carefully because of possible withdrawal symptoms such as dizziness, irritability, and flu-like symptoms. A gradual taper is recommended to minimize these effects. Extended-release venlafaxine is an effective treatment option for people with PTSD, especially those who do not respond well to selective serotonin reuptake inhibitors(SSRIs). Its dual action on serotonin and norepinephrine makes it an interesting alternative, especially given its favourable remission rates and general tolerability in clinical studies[33].

DOSING AND SIDE EFFECTS OF PTSD MEDICATIONS[2,3,7]

Drug	Dose	Side effects
First-Line Treatments		
Selective Serotonin Reuptake Inhibitors (SSRIs)		
Fluoxetine	**Starting Dose:**20mg/day Maximun dose: 60mg/day	Nausea, Diarrhea, Dry Mouth, Headache, Fatigue or Weakness, Insomnia and Sleep Disturbances, Sexual Dysfunction, Increased Anxiety or Nervousness, Tremors.
Sertraline	Starting Dose: 25 mg once daily. Maximum recommended dose: 200 mg per day.	Insomnia, nausea, diarrhea, dry mouth, fatigue, and sexual dysfunction.
Paroxetine	Initiate on 20mg/day. maximum of 60mg/day	Sexual problems, nausea, vomiting, diarrhea, or constipation, Trouble sleeping, sweating, Weakness, Headache, Blurry vision, Dizziness, Severe Allergic Reactions, Suicidal Thoughts
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)		
Venlafaxine	Initiate on 75mg/day. maximum of 300mg/day	Nausea, Dizziness, Dry mouth, Increased blood pressure, Sexual dysfunction
Second-Line Treatments		
Prazosin	Starting dose : 1mg	Dizziness, Headache, Drowsiness, Nausea,

	Maximum dose : 20-25mg	Palpitations, hypotension.
Quetiapine	Initiate 25mg/day at night. maximum of 400mg/day.	Dry mouth, dizziness, Abdominal pain, constipation, weight gain, trouble moving, rapid heartbeat, Weakness, Suicidal thoughts or actions, Neuroleptic malignant syndrome, Hyperglycemia, Orthostatic hypotension
Other Medications		
Amitriptyline	Starting dose:25mg to 50 mg Maintanance dose : 100mg per day	Sedation, Weight Gain, dry mouth, constipation, blurred vision, arrhythmias
Risperidone	Starting dose: 0.5mg per day Maintanance dose : 1mg to 4mg per day	Weight gain, sedation, and metabolic changes. Extra-pyramidal Symptoms. Hormonal Changes: lead sexual dysfunction or galactorrhea.
Imipramine	Starting dose: 25mg to 50mg per day Maintanance dose : 200mg per day	Sedation, dry mouth, constipation, and urinary retention
Mirtazapine	Starting dose:15mg to 30mg per day Maintanance dose : 45mg per day	Sedation, increased appetite, and weight gain.
Phenelzine	Starting dose: 15mg/day Maintanance dose : 90mg/day	Dizziness, Drowsiness, Headache, Dry mouth, Constipation , urinary retention, Weight gain, Sexual dysfunction, Tremors, Seizures, Suicidal thoughts, Serotonin syndrome.

SECOND LINE THERAPY FOR PTSD

Prazosin

Prazosin, an alpha-1 adrenergic receptor antagonist originally developed for hypertension, has attracted attention for its off-label use in the treatment of posttraumatic stress disorder (PTSD), particularly to relieve anxiety and improve sleep quality.

Numerous studies have evaluated the efficacy of prazosin in managing PTSD symptoms, particularly those related to sleep disturbances and anxiety. Patients taking prazosin have reported improved sleep quality and a reduction in hyperarousal symptoms, which are common in PTSD[34]. Its efficacy is attributed to its ability to cross the blood-brain barrier and antagonize alpha-1 receptors in the central nervous system. This action helps to alleviate the autonomic arousal caused by PTSD, thereby reducing the intensity of nightmares and improving sleep quality[35]. Due to its potential to cause hypotension, prazosin should be prescribed with caution in patients already receiving antihypertensive medications. Prazosin represents a promising option for the treatment of PTSD, particularly in patients suffering from distressing anxiety and sleep disturbances. Although it is not a first-line treatment for all symptoms of PTSD, its specific efficacy in treating sleep problems makes it a valuable adjunctive treatment. Further large-scale studies are needed to consolidate its role in PTSD treatment protocols and to explore its potential benefits in acute cases or as a preventive measure after exposure to trauma.

Quetiapine

Quetiapine, an atypical antipsychotic, has been studied for its efficacy in the treatment of post-traumatic stress disorder (PTSD), particularly in cases where traditional treatments have not been effective. Quetiapine acts on various neurotransmitter receptors, including dopaminergic (D1, D2, D3, D4), serotonergic (5-HT2A, 5-HT2C, 5-HT7), adrenergic (α1), histamine (H1) and muscarinic (mACh) receptors. These actions contribute to its mood-stabilizing and anxiety-reducing effects, which are useful in the treatment of PTSD. Research shows that quetiapine can improve general symptoms of PTSD, including reducing the severity of reexperiencing, symptoms of hyperarousal, and reducing associated depression and anxiety[36].

The effects of quetiapine on individual PTSD symptoms have been examined, showing significant improvements in insomnia and intrusive memories, faster reaction times for symptoms such as irritability, and disturbing dreams. Although quetiapine is not a first-line treatment for PTSD where trauma-focused therapy is preferred, it is recommended as a second-line option or as an add-on treatment when first-line treatments (SSRIs or SNRIs) are ineffective or not tolerated[37].

OTHER MEDICATION

Amitriptyline

Amitriptyline, a tricyclic antidepressant (TCA), has been studied for its role in the treatment of post-traumatic stress disorder (PTSD). Although it is not generally a first-line treatment, it may be useful in some cases, especially when patients have comorbidities such as depression or anxiety. Current guidelines recommend trauma-focused psychological therapies as first-line treatment for PTSD. Amitriptyline may be considered as a second-line option when first-line treatments are ineffective or in the presence of significant concomitant depression or anxiety[37].

Amitriptyline may offer some benefit to people with PTSD, particularly those with co-occurring depressive symptoms. However, its use should be carefully evaluated based on the potential side effects and ideally combined with psychotherapy for optimal results. More research is needed to establish its definitive role in PTSD treatment protocols.

Risperidone

Risperidone, an atypical antipsychotic, is often used as an add-on treatment to standard therapies, particularly for patients with treatment-resistant symptoms. Low doses of risperidone may help reduce specific PTSD symptoms, such as irritability and intrusive thoughts. In a large study, veterans with military PTSD who had failed to respond to at least two adequate serotonin reuptake inhibitor (SRI) treatments were given risperidone (up to 4 mg daily) or a placebo. Results showed no significant difference in reduction of PTSD symptoms between the two groups after six months[38]. Although several smaller studies have reported positive results[39], the use of risperidone in the treatment of PTSD remains controversial, but it may offer some benefit for specific symptoms, such as irritability and intrusive thoughts. In addition, the risk of adverse effects must be carefully weighed against the potential benefits. Current guidelines do not generally recommend risperidone as a first-line treatment for PTSD, but suggest that it may be considered in some cases, especially when other treatments have failed[39].

Phenelzine

Phenelzine, a non-selective and irreversible Monoamine oxidase inhibitor (MAOI), is primarily used to treat major depressive disorder, but has also been studied for its effectiveness in managing post-traumatic stress disorder (PTSD). Phenelzine works by inhibiting the breakdown of key neurotransmitters such as serotonin, norepinephrine, and dopamine, leading to increased levels of these chemicals in the brain. This action is thought to contribute to its antidepressant and anxiolytic effects, which may be particularly helpful for people with PTSD who often experience anxiety and depression as part of their symptoms. Several studies have explored the effectiveness of phenelzine in the treatment of PTSD. In an 8-week trial involving male veterans, phenelzine showed a 44% improvement in PTSD symptoms, as measured by the Impact of Events Scale (IES). Pilot studies have shown that phenelzine may be helpful for PTSD symptoms, particularly in cases where other treatments have failed. The use of phenelzine in the treatment of PTSD remains largely off-label and may be considered primarily in patients who do not respond to standard treatments or who have treatment-resistant symptoms[40].

Imipramine

Imipramine a tricyclic antidepressant (TCA), has been studied for its effectiveness in the treatment of posttraumatic stress disorder (PTSD). Although it is primarily indicated for depression, its use in the treatment of PTSD is considered an off-label application. Research shows that imipramine can significantly reduce PTSD symptoms. In a study of Vietnam War veterans, imipramine demonstrated a 25% reduction in PTSD symptoms, as measured by the Impact of Events Scale (IES) after five weeks of treatment, compared with only a 5% improvement in the placebo group[40].

Another clinical trial showed that imipramine and phenelzine (another antidepressant) were both effective in alleviating PTSD symptoms, although phenelzine showed a higher rate of improvement[41]. The effectiveness of imipramine appears to be particularly evident for intrusive symptoms of PTSD rather than avoidance symptoms[40]. Imipramine works primarily by inhibiting the reuptake of two neurotransmitters: serotonin and norepinephrine. This action increases the levels of these neurotransmitters in the synaptic cleft, which is thought to contribute to its antidepressant effects. In particular, imipramine has a stronger propensity to inhibit the reuptake of serotonin than norepinephrine, which may play a role in its effectiveness against PTSD symptoms that include mood and anxiety. Due to the rise of selective serotonin reuptake inhibitors (SSRIs) such as sertraline and paroxetine, which generally have a more favorable side effect profile, imipramine is less commonly prescribed today for PTSD[41].

Mirtazapine

Mirtazapine, a specific non-adrenergic and serotonergic antidepressant (NaSSA), has been investigated for its potential use in the treatment of post-traumatic stress disorder (PTSD). Mirtazapine functions by enhancing noradrenergic and serotonergic neurotransmission. It antagonizes several serotonin receptors while simultaneously increasing the release of norepinephrine. This dual action may contribute to its antidepressant effects and potential efficacy in alleviating anxiety and mood disorders associated with PTSD. Research on the effectiveness of Mirtazapine in PTSD shows mixed results. Early studies indicate that Mirtazapine may result in clinical improvement in approximately 50% of patients with severe chronic PTSD. Recent findings indicate that mirtazapine may not be effective as monotherapy for PTSD.

In a pilot study, subjects showed a significant reduction in PTSD symptoms after 8 weeks of treatment at doses up to 45 mg/day. Another study reported a response rate of 65% in patients treated with mirtazapine compared with only 20% for placebo[40]. An open-label study of veterans with PTSD in combat suggests that mirtazapine can effectively reduce symptoms, with significant improvements observed in various PTSD rating scales[42]. In a

comparative study, Mirtazapine showed higher response rates (88%) than sertraline (69%) in veterans with PTSD[40]. These results suggest that Mirtazapine may be particularly useful for people who do not respond well to selective serotonin reuptake inhibitors (SSRIs). A randomized controlled trial indicated that there was no notable difference in reducing PTSD symptoms between mirtazapine and placebo during the controlled treatment period. However, improvements were observed in secondary endpoints related to depression and sleep quality during an open phase after the initial trial[43].

CONCLUSION

PTSD is a complex and debilitating condition that requires a comprehensive treatment approach. A range of pharmacological and psychological therapies are available for PTSD management, each with its own strengths and limitations. A personalized treatment plan, incorporating a combination of therapies, can optimize outcomes for individuals with PTSD. The development and implementation of digital mental health interventions, including virtually reality may enhance access to PTSD care and improve treatment outcomes.

REFERENCE :

1. Merians AN, Spiller T, Harpaz-Rotem I, Krystal JH, Pietrzak RH. Post-traumatic stress disorder. Medical Clinics. 2023 Jan 1;107(1):85-99.
2. Al Jowf GI, Ahmed ZT, An N, Reijnders RA, Ambrosino E, Rutten BP, de Nijs L, Eijssen LM. A public health perspective of post-traumatic stress disorder. International journal of environmental research and public health. 2022 May 26;19(11):6474.
3. Yehuda R, Hoge CW, McFarlane AC, Vermetten E, Lanius RA, Nievergelt CM, Hobfoll SE, Koenen KC, Neylan TC, Hyman SE. Post-traumatic stress disorder. Nature reviews Disease primers. 2015 Oct 8;1(1):1-22.
4. Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. New England journal of medicine. 2017 Jun 22;376(25):2459-69
5. Koirala R, Søegaard EG, Thapa SB. Updates on pharmacological treatment of post-traumatic stress disorder. Journal of Nepal Medical Association. 2017;56(206):274-80.
6. Steel Z, Chey T, Silove D, Marnane C, Bryant RA, Van Ommeren M. Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis. Jama. 2009 Aug 5;302(5):537-49.
7. Breslau N. Epidemiologic studies of trauma, posttraumatic stress disorder, and other psychiatric disorders. The Canadian Journal of Psychiatry. 2002 Dec;47(10):923-9.
8. Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba O, Wang Y, King S, Levinson W, Guerin A, Lefebvre P, Davis LL. Prevalence of post-traumatic stress disorder in the United States: a systematic literature review. Current medical research and opinion. 2021 Dec 2;37(12):2151-61.
9. Harm M, Hope M, Household A. American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders, 5th edn, Washington, DC: American Psychiatric Association Anderson, J, Sapey, B, Spandler, H (eds), 2012, Distress or Disability?, Lancaster: Centre for Disability Research, www. lancaster. ac. uk. Arya.;347:64.
10. Bryant RA. Acute stress disorder as a predictor of posttraumatic stress disorder: a systematic review. The Journal of clinical psychiatry. 2010 Dec 14;71(2):381
11. .Astill Wright L, Sijbrandij M, Sinnerton R, Lewis C, Roberts NP, Bisson JI. Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. Translational psychiatry. 2019 Dec 9;9(1):334.
12. Rothbaum BO, Kearns MC, Price M, Malcoun E, Davis M, Ressler KJ, Lang D, Houry D. Early intervention may prevent the development of posttraumatic stress disorder: a randomized pilot civilian study with modified prolonged exposure. Biological psychiatry. 2012 Dec 1;72(11):957-63.
13. Zatzick D, Roy-Byrne P, Russo J, Rivara F, Droesch R, Wagner A, Dunn C, Jurkovich G, Uehara E, Katon W. A randomized effectiveness trial of stepped collaborative care foracutely injured trauma survivors. Archives of general psychiatry. 2004 May 1;61(5):498-506.
14. Ostacher MJ, Cifu AS. Management of posttraumatic stress disorder. Jama. 2019 Jan 15;321(2):200-1.
15. Cusack K, Jonas DE, Forneris CA, Wines C, Sonis J, Middleton JC, Feltner C, Brownley KA, Olmsted KR, Greenblatt A, Weil A. Psychological treatments for adults with posttraumatic stress disorder: A systematic review and meta-analysis. Clinical psychology review. 2016 Feb 1;43:128-41.
16. Lewis C, Roberts NP, Andrew M, Starling E, Bisson JI. Psychological therapies for post-traumatic stress disorder in adults: Systematic review and meta-analysis. European journal of psychotraumatology. 2020 Dec 31;11(1):1729633

17. Cuijpers P, Veen SC, Sijbrandij M, Yoder W, Cristea IA. Eye movement desensitization and reprocessing for mental health problems: A systematic review and meta-analysis. Cognitive Behaviour Therapy. 2020 May 3;49(3):165-80.

18. Mavranezouli I, Megnin-Viggars O, Daly C, Dias S, Welton NJ, Stockton S, Bhutani G, Grey N, Leach J, Greenberg N, Katona C. Psychological treatments for post-traumatic stress disorder in adults: A network meta-analysis. Psychological medicine. 2020 Mar;50(4):542-55.

19. Weber M, Schumacher S, Hannig W, Barth J, Lotzin A, Schäfer I, Ehring T, Kleim B. Long-term outcomes of psychological treatment for posttraumatic stress disorder: A systematic review and meta-analysis. Psychological Medicine. 2021 Jul;51(9):1420-30.

20. Visser E, Gosens T, Den Oudsten BL, De Vries J. The course, prediction, and treatment of acute and posttraumatic stress in trauma patients: a systematic review. Journal of Trauma and Acute Care Surgery. 2017 Jun 1;82(6):1158-83.

21. Guina J. Rossetter, SR-Derhodes, BJ-Nahhas, RW & Welton, RS (2015). Benzodiazepines for PTSD. Journal of Psychiatric Practice.;21(4):281-303.

22. de Moraes Costa G, Zanatta FB, Ziegelmann PK, Barros AJ, Mello CF. Pharmacological treatments for adults with post-traumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability. Journal of psychiatric research. 2020 Nov 1;130:412-20.

23. Villarreal G, Hamner MB, Cañive JM, Robert S, Calais LA, Durklaski V, Zhai Y, Qualls C. Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American journal of psychiatry. 2016 Dec 1;173(12):1205-12.

24. Li W, Ma YB, Yang Q, Li BL, Meng QG, Zhang Y. Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International journal of psychiatry in clinical practice. 2017 Apr 3;21(2):151-5.

25. Davidson J, Roth S, Newman E. Fluoxetine in post-traumatic stress disorder.

26. Connor KM, Sutherland SM, Tupler LA, Malik ML, Jonathan R, Davidson T. Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. The British Journal of Psychiatry. 1999 Jul;175(1):17-22

27. Xu JJ, Chan MJ, Yang YC. Fluoxetine as a treatment for post-traumatic stress disorder. Neurosciences Journal. 2011 Jul 1;16(3):257-62.

28. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. Jama. 2000 Apr 12;283(14):1837-44.

29. Graham B, Garcia NM, Bergman HE, Feeny NC, Zoellner LA. Prolonged exposure and sertraline treatments for posttraumatic stress disorder also improve multiple indicators of social functioning. Journal of traumatic stress. 2020 Aug;33(4):488-99.

30. American Psychological Association. Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults.

31. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). International Journal of Neuropsychopharmacology. 2012 Jul 1;15(6):825-40.

32. Huang ZD, Zhao YF, Li S, Gu HY, Lin LL, Yang ZY, Niu YM, Zhang C, Luo J. Comparative efficacy and acceptability of pharmaceutical management for adults with post-traumatic stress disorder: a systematic review and meta-analysis. Frontiers in pharmacology. 2020 May 8;11:559.

33. Hoskins M, Pearce J, Bethell A, et al. Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. *British Journal of Psychiatry*. 2015;206(2):93-100.

34. Richardson C, Swartz A, Forsberg M. Prazosin dosed 3 times a day to treat flashbacks related to PTSD: A case report. Mental Health Clinician. 2022 Aug 1;12(4):267-9.

35. Togno J, Eaton S. Is there a role for prazosin in the treatment of post-traumatic stress disorder?. Australian family physician. 2015 Sep;44(9):647-9.

36. Villarreal G, Hamner MB, Cañive JM, Robert S, Calais LA, Durklaski V, Zhai Y, Qualls C. Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American journal of psychiatry. 2016 Dec 1;173(12):1205-12.

37. Phelps AJ, Lethbridge R, Brennan S, Bryant RA, Burns P, Cooper JA, Forbes D, Gardiner J, Gee G, Jones K, Kenardy J. Australian guidelines for the prevention and treatment of posttraumatic stress disorder: Updates in the third edition. Australian & New Zealand Journal of Psychiatry. 2022 Mar;56(3):230-47.

38. Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, Horney RA, Huang GD, Stock C, Veterans Affairs Cooperative Study No. 504 Group. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service–related PTSD: A randomized trial. Jama. 2011 Aug 3;306(5):493-502.

39. Connell R, Zeier K, Thomas CJ. A review of atypical antipsychotics and their utility in post-traumatic stress disorder. Mental Health Clinician. 2013 Jan 1;2(7):187-94.

40. Song J, Chae J. Update on current treatment options for posttraumatic stress disorder. Psychiatry Investigation. 2005 Sep;2(2):31.

41. Yan JZ, Liu JL, Li XZ, Zhang ZX, Liu RB, Zhang C, Gong QQ. Effectiveness, acceptability and safety of pharmaceutical management for combat-related PTSD in adults based on systematic review of twenty-two randomized controlled trials. Frontiers in Pharmacology. 2022 Jan 18;12:805354.

42. .Alderman CP, Condon JT, Gilbert AL. An open-label study of mirtazapine as treatment for combat-related PTSD. Annals of Pharmacotherapy. 2009 Jul;43(7-8):1220-6.

43. Bryant RA, Friedman M. Medication and non-medication treatments of post-traumatic stress disorder. Current Opinion in Psychiatry. 2001 Mar 1;14(2):119-23.